ArticlebioRxiv : the preprint server for biology2025
Noninvasive focal gene transfer of chemogenetic proteins in the primate brain.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of chemogenetic neuromodulators, including Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), have enabled focally specific, long-lasting, and reversible neuromodulation in the primate brain. Although systemically delivered synthetic ligands allow for noninvasive actuation of chemogenetic receptors, direct intraparenchymal injection remains atop the available methods to precisely deliver chemogenetic payloads to a specific target of the brain. The requirement of trephination, however, is accompanied by inherent risks of infection, long recovery times, and often tissue damage with concomitant behavioral complications. When considering therapeutic injections, the requirement of transcranial surgery does not translate well to the clinic, especially when repeated administrations are required. Here, we leverage our recent development of transcranial focused ultrasound (tFUS) for noninvasive and focal delivery of adeno-associated viruses (AAVs) carrying excitatory Gq-DREADDs to frontal cortical targets (areas 6DR and 8aD) in the marmoset brain. Using [
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.